Voyager Therapeutics (NASDAQ:VYGR) Stock Price Crosses Below Fifty Day Moving Average – What’s Next?

Voyager Therapeutics, Inc. (NASDAQ:VYGR)’s share price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $3.90 and traded as low as $3.55. Voyager Therapeutics shares last traded at $3.62, with a volume of 569,541 shares changing hands.

Analyst Ratings Changes

A number of research analysts recently issued reports on VYGR shares. Wall Street Zen lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright restated a “buy” rating on shares of Voyager Therapeutics in a research report on Tuesday, May 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Voyager Therapeutics in a research report on Wednesday, April 15th. Finally, Truist Financial upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Voyager Therapeutics Stock Up 0.6%

The stock’s 50-day moving average price is $3.90 and its 200-day moving average price is $3.97. The company has a market capitalization of $218.72 million, a price-to-earnings ratio of -1.84 and a beta of 1.25.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%. The company had revenue of $1.19 million for the quarter, compared to analyst estimates of $8.79 million. On average, equities research analysts anticipate that Voyager Therapeutics, Inc. will post -1.61 EPS for the current year.

Insider Buying and Selling at Voyager Therapeutics

In related news, CEO Alfred Sandrock sold 11,511 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total transaction of $44,547.57. Following the completion of the sale, the chief executive officer directly owned 472,549 shares of the company’s stock, valued at $1,828,764.63. The trade was a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 12.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Voyager Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of VYGR. Wexford Capital LP bought a new stake in Voyager Therapeutics in the third quarter valued at approximately $42,000. ProShare Advisors LLC bought a new stake in shares of Voyager Therapeutics during the fourth quarter worth $44,000. CIBC Asset Management Inc bought a new stake in shares of Voyager Therapeutics during the fourth quarter worth $45,000. Coldstream Capital Management Inc. acquired a new position in Voyager Therapeutics during the third quarter worth $55,000. Finally, EHP Funds Inc. acquired a new position in Voyager Therapeutics during the third quarter worth $58,000. 48.03% of the stock is owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.